Vaccine regs amended
Executive Summary
To make clinical testing requirement more flexible and consistent with current scientific knowledge for measles virus vaccine live, mumps virus vaccine live and rubella virus vaccine live, FDA announced in a Nov. 16 Federal Register notice. The amendment, which becomes effective on Dec. 16, removes the consecutive lot requirement for clinical trials; eliminates requirement for prescribed lot tests to allow alternative testing; is changed to allow alternative routes of vaccine administration; and amended to allow mumps vaccine safety test only on chick embryo kidneys, not liver. According to the amendment, rubella virus may now be propagated in cell culture lines other than duck embryo cell cultures, and rabbit renal cultures. Additional standards for measles and smallpox vaccines have been dropped.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.